Maximum quantity allowed is 999
CAS RN: 2207-75-2 | Product Number: O0164
Potassium Oxonate
Purity: >98.0%(T)(HPLC)
- Allantoxanic Acid Potassium Salt
- Oxonic Acid Potassium Salt
- Potassium Allantoxanate
- Potassium 4,6-Dihydroxy-1,3,5-triazine-2-carboxylate
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 5G |
$51.00
|
5 | 10 | Contact Us | |
| 25G |
$156.00
|
5 | ≥100 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | O0164 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__4H__2KN__3O__4 = 195.18 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 2207-75-2 |
Related CAS RN
|
937-13-3 |
| Reaxys Registry Number | 4049961 |
| PubChem Substance ID | 87574167 |
| MDL Number | MFCD00010565 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting Point | 300 °C |
| RTECS# | RR4580000 |
| H.S.code* | 2933.69-000 |
References
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats
- Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
- Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
References
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
- Hyperuricemia induced by some antihypertensives and uricosuric drugs in oxonate-treated rats
- Y. Yonetani, M. Ishii, K. Iwaki, Jpn. J. Pharmacol. 1980, 30, 829.
- Use of the uricase-inhibited rat as an animal model in toxicology
- Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.